Preservation of β-cell function by targeting β-cell mass

Trends in Pharmacological Sciences

Volumn 29, Issue 4, 2008, Pages 218-227

  de Koning, Eelco J P ^a   Bonner Weir, Susan ^b   Rabelink, Ton J ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b HARVARD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EXENDIN 4; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE; I KAPPA B; LIRAGLUTIDE; METFORMIN; PIOGLITAZONE; ROSIGLITAZONE; SALICYLATE SODIUM; SITAGLIPTIN; TELMISARTAN; TROGLITAZONE; VILDAGLIPTIN;

APOPTOSIS; CELL FUNCTION; CELL LOSS; CELL SURVIVAL; DRUG TARGETING; ENDOTHELIAL DYSFUNCTION; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; INSULIN RELEASE; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; CYTOKINES; CYTOPROTECTION; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN-SECRETING CELLS; NF-KAPPA B; OBESITY; RECEPTORS, GLUCAGON; RENIN-ANGIOTENSIN SYSTEM;

EID: 41349117978     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tips.2008.02.001     Document Type: Review

References (117)

1. Wild S., et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27 (2004) 1047-1053
2. Kahn S.E., et al. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 444 (2006) 840-846
3. Bonner-Weir S. Perspective: postnatal pancreatic β-cell growth. Endocrinology 141 (2000) 1926-1929
4. Terauchi Y., et al. Glucokinase and IRS-2 are required for compensatory β-cell hyperplasia in response to high-fat diet-induced insulin resistance. J. Clin. Invest. 117 (2007) 246-257
5. Weir G.C., and Bonner-Weir S. A dominant role for glucose in β-cell compensation of insulin resistance. J. Clin. Invest. 117 (2007) 81-83
6. Butler A.E., et al. β-Cell deficit and increased β-cell apoptosis in humans with type 2 diabetes. Diabetes 52 (2003) 102-110
7. Kloppel G., et al. Islet pathology and the pathogenesis of type 1 and type 2 diabetes mellitus revisited. Surv. Synth. Pathol. Res. 4 (1985) 110-125
8. Hansen B.C., and Bodkin N.L. Heterogeneity of insulin responses: phases leading to type 2 (non-insulin-dependent) diabetes mellitus in the rhesus monkey. Diabetologia 29 (1986) 713-719
9. de Koning E.J., et al. Diabetes mellitus in Macaca mulatta monkeys is characterised by islet amyloidosis and reduction in β-cell population. Diabetologia 36 (1993) 378-384
10. Sakuraba H., et al. Reduced β-cell mass and expression of oxidative stress-related DNA damage in the islet of Japanese type II diabetic patients. Diabetologia 45 (2002) 85-96
11. Yoon K.H., et al. Selective β-cell loss and α-cell expansion in patients with type 2 diabetes mellitus in Korea. J. Clin. Endocrinol. Metab. 88 (2003) 2300-2308
12. Pick A., et al. Role of apoptosis in failure of β-cell mass compensation for insulin resistance and β-cell defects in the male Zucker diabetic fatty rat. Diabetes 47 (1998) 358-364
13. Danial N.N., et al. Dual role of proapoptotic BAD in insulin secretion and β-cell survival. Nat. Med. 14 (2008) 144-153
14. Kendall D.M., et al. Effects of hemipancreatectomy on insulin secretion and glucose tolerance in healthy humans. N. Engl. J. Med. 322 (1990) 898-903
15. Leahy J.L., et al. Minimal chronic hyperglycemia is a critical determinant of impaired insulin secretion after an incomplete pancreatectomy. J. Clin. Invest. 81 (1988) 1407-1414
16. Finegood D.T., et al. Dynamics of β-cell mass in the growing rat pancreas. Estimation with a simple mathematical model. Diabetes 44 (1995) 249-256
17. Matveyenko A.V., et al. Mechanisms of impaired fasting glucose and glucose intolerance induced by an approximate 50% pancreatectomy. Diabetes 55 (2006) 2347-2356
18. Kjems L.L., et al. Decrease in β-cell mass leads to impaired pulsatile insulin secretion, reduced postprandial hepatic insulin clearance, and relative hyperglucagonemia in the minipig. Diabetes 50 (2001) 2001-2012
19. Goodner C.J., et al. Decreased insulin- and glucagon-pulse amplitude accompanying β-cell deficiency induced by streptozocin in baboons. Diabetes 38 (1989) 925-931
20. Robertson R.P. Chronic oxidative stress as a central mechanism for glucose toxicity in pancreatic islet β-cells in diabetes. J. Biol. Chem. 279 (2004) 42351-42354
21. Leahy J.L., et al. β-Cell dysfunction induced by chronic hyperglycemia. Current ideas on mechanism of impaired glucose-induced insulin secretion. Diabetes Care 15 (1992) 442-455
22. Laybutt D.R., et al. Critical reduction in β-cell mass results in two distinct outcomes over time. Adaptation with impaired glucose tolerance or decompensated diabetes. J. Biol. Chem. 278 (2003) 2997-3005
23. Pickup J.C., et al. NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia 40 (1997) 1286-1292
24. Shoelson S.E., et al. Inflammation and insulin resistance. J. Clin. Invest. 116 (2006) 1793-1801
25. Donath M.Y., et al. Inflammatory mediators and islet β-cell failure: a link between type 1 and type 2 diabetes. J. Mol. Med. 81 (2003) 455-470
26. Haffner S.M., et al. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 106 (2002) 679-684
27. Haffner S., et al. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes 54 (2005) 1566-1572
28. Maedler K., et al. Glucose-induced β-cell production of IL-1β contributes to glucotoxicity in human pancreatic islets. J. Clin. Invest. 110 (2002) 851-860
29. Maedler K., et al. Leptin modulates β-cell expression of IL-1 receptor antagonist and release of IL-1β in human islets. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 8138-8143
30. Larsen C.M., et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N. Engl. J. Med. 356 (2007) 1517-1526
31. Lau T., et al. Evidence for a local angiotensin-generating system and dose-dependent inhibition of glucose-stimulated insulin release by angiotensin II in isolated pancreatic islets. Diabetologia 47 (2004) 240-248
32. Lai E.Y., et al. Vascular reactivity in arterioles from normal and alloxan-diabetic mice: studies on single perfused islets. Diabetes 56 (2007) 107-112
33. Kampf C., et al. Angiotensin II type 1 receptor inhibition markedly improves the blood perfusion, oxygen tension and first phase of glucose-stimulated insulin secretion in revascularised syngeneic mouse islet grafts. Diabetologia 48 (2005) 1159-1167
34. Jandeleit-Dahm K.A., et al. Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes. J. Hypertens. 23 (2005) 463-473
35. Schupp M., et al. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-γ activity. Circulation 109 (2004) 2054-2057
36. Tikellis C., et al. Improved islet morphology after blockade of the renin-angiotensin system in the ZDF rat. Diabetes 53 (2004) 989-997
37. Lammert E., et al. Induction of pancreatic differentiation by signals from blood vessels. Science 294 (2001) 564-567
38. Lammert E., et al. Role of VEGF-A in vascularization of pancreatic islets. Curr. Biol. 13 (2003) 1070-1074
39. Johansson M., et al. Islet endothelial cells and pancreatic β-cell proliferation: studies in vitro and during pregnancy in adult rats. Endocrinology 147 (2006) 2315-2324
40. Vasir B., et al. Hypoxia induces vascular endothelial growth factor gene and protein expression in cultured rat islet cells. Diabetes 47 (1998) 1894-1903
41. Iwashita N., et al. Impaired insulin secretion in vivo but enhanced insulin secretion from isolated islets in pancreatic β-cell-specific vascular endothelial growth factor-A knock-out mice. Diabetologia 50 (2007) 380-389
42. Brissova M., et al. Pancreatic islet production of vascular endothelial growth factor-A is essential for islet vascularization, revascularization, and function. Diabetes 55 (2006) 2974-2985
43. Homo-Delarche F., et al. Islet inflammation and fibrosis in a spontaneous model of type 2 diabetes, the GK rat. Diabetes 55 (2006) 1625-1633
44. Li X., et al. Islet microvasculature in islet hyperplasia and failure in a model of type 2 diabetes. Diabetes 55 (2006) 2965-2973
45. Mizuno A., et al. Changes in islet capillary angioarchitecture coincide with impaired β-cell function but not with insulin resistance in male Otsuka-Long-Evans-Tokushima fatty rats: dimorphism of the diabetic phenotype at an advanced age. Metabolism 48 (1999) 477-483
46. Rask-Madsen C., and King G.L. Mechanisms of disease: endothelial dysfunction in insulin resistance and diabetes. Nat. Clin. Pract. Endocrinol. Metab. 3 (2007) 46-56
47. Lai E.Y., et al. Endothelin-1 and pancreatic islet vasculature: studies in vivo and on isolated, vascularly perfused pancreatic islets. Am. J. Physiol. Endocrinol. Metab. 292 (2007) E1616-E1623
48. Carlsson P.O., et al. Islet capillary blood pressure increase mediated by hyperglycemia in NIDDM GK rats. Diabetes 46 (1997) 947-952
49. Carlsson P.O., et al. Angiotensin II and the endocrine pancreas: effects on islet blood flow and insulin secretion in rats. Diabetologia 41 (1998) 127-133
50. Olsson R., and Carlsson P.O. The pancreatic islet endothelial cell: emerging roles in islet function and disease. Int. J. Biochem. Cell Biol. 38 (2006) 710-714
51. Rabelink T.J., et al. Peritubular endothelium: the Achilles heel of the kidney?. Kidney Int. 72 (2007) 926-930
52. Drucker D.J., and Nauck M.A. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368 (2006) 1696-1705
53. Holst J.J. The physiology of glucagon-like peptide 1. Physiol. Rev. 87 (2007) 1409-1439
54. Susini S., et al. Glucose and glucoincretin peptides synergize to induce c-fos, c-jun, junB, zif-268, and nur-77 gene expression in pancreatic β (INS-1) cells. FASEB J. 12 (1998) 1173-1182
55. Nauck M., et al. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 29 (1986) 46-52
56. Vilsboll T., et al. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes 50 (2001) 609-613
57. Rachman J., et al. Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM. Diabetologia 40 (1997) 205-211
58. Rachman J., et al. Normalization of insulin responses to glucose by overnight infusion of glucagon-like peptide 1 (7-36) amide in patients with NIDDM. Diabetes 45 (1996) 1524-1530
59. Toft-Nielsen M.B., et al. Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients. Diabetes Care 22 (1999) 1137-1143
60. Zander M., et al. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: a parallel-group study. Lancet 359 (2002) 824-830
61. Kjems L.L., et al. The influence of GLP-1 on glucose-stimulated insulin secretion: effects on β-cell sensitivity in type 2 and nondiabetic subjects. Diabetes 52 (2003) 380-386
62. Xu G., et al. Downregulation of GLP-1 and GIP receptor expression by hyperglycemia: possible contribution to impaired incretin effects in diabetes. Diabetes 56 (2007) 1551-1558
63. Vilsboll T., et al. Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects. Regul. Pept. 114 (2003) 115-121
64. Nauck M.A., et al. Preserved incretin activity of glucagon-like peptide 1 (7-36 amide) but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J. Clin. Invest. 91 (1993) 301-307
65. Heine R.J., et al. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann. Intern. Med. 143 (2005) 559-569
66. Bregenholt S., et al. The long-acting glucagon-like peptide-1 analogue, liraglutide, inhibits β-cell apoptosis in vitro. Biochem. Biophys. Res. Commun. 330 (2005) 577-584
67. Buteau J., et al. Glucagon-like peptide-1 prevents β-cell glucolipotoxicity. Diabetologia 47 (2004) 806-815
68. Li L., et al. Glucagon-like peptide-1 protects β-cells from cytokine-induced apoptosis and necrosis: role of protein kinase B. Diabetologia 48 (2005) 1339-1349
69. Li Y., et al. Glucagon-like peptide-1 receptor signaling modulates β-cell apoptosis. J. Biol. Chem. 278 (2003) 471-478
70. Farilla L., et al. Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology 144 (2003) 5149-5158
71. Farilla L., et al. Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats. Endocrinology 143 (2002) 4397-4408
72. Wang Q., and Brubaker P.L. Glucagon-like peptide-1 treatment delays the onset of diabetes in 8 week-old db/db mice. Diabetologia 45 (2002) 1263-1273
73. Hui H., et al. Glucagon-like peptide-1 inhibits apoptosis of insulin-secreting cells via a cyclic 5′-adenosine monophosphate-dependent protein kinase A- and a phosphatidylinositol 3-kinase-dependent pathway. Endocrinology 144 (2003) 1444-1455
74. Kwon G., et al. cAMP dose-dependently prevents palmitate-induced apoptosis by both protein kinase A- and cAMP-guanine nucleotide exchange factor-dependent pathways in β-cells. J. Biol. Chem. 279 (2004) 8938-8945
75. Sarkar S.A., et al. Dominant negative mutant forms of the cAMP response element binding protein induce apoptosis and decrease the anti-apoptotic action of growth factors in human islets. Diabetologia 50 (2007) 1649-1659
76. Jhala U.S., et al. cAMP promotes pancreatic β-cell survival via CREB-mediated induction of IRS2. Genes Dev. 17 (2003) 1575-1580
77. Goldstein B.J., et al. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care 30 (2007) 1979-1987
78. Hansotia T., et al. Double incretin receptor knockout (DIRKO) mice reveal an essential role for the enteroinsular axis in transducing the glucoregulatory actions of DPP-IV inhibitors. Diabetes 53 (2004) 1326-1335
79. Conarello S.L., et al. Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 6825-6830
80. Pospisilik J.A., et al. Dipeptidyl peptidase IV inhibitor treatment stimulates β-cell survival and islet neogenesis in streptozotocin-induced diabetic rats. Diabetes 52 (2003) 741-750
81. Mu J., et al. Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic β-cell mass and function in a rodent model of type 2 diabetes. Diabetes 55 (2006) 1695-1704
82. Yasuda N., et al. Enhanced secretion of glucagon-like peptide 1 by biguanide compounds. Biochem. Biophys. Res. Commun. 298 (2002) 779-784
83. Marchetti P., et al. Pancreatic islets from type 2 diabetic patients have functional defects and increased apoptosis that are ameliorated by metformin. J. Clin. Endocrinol. Metab. 89 (2004) 5535-5541
84. Lupi R., et al. Rosiglitazone prevents the impairment of human islet function induced by fatty acids: evidence for a role of PPAR-γ2 in the modulation of insulin secretion. Am. J. Physiol. Endocrinol. Metab. 286 (2004) E560-E567
85. Zeender E., et al. Pioglitazone and sodium salicylate protect human β-cells against apoptosis and impaired function induced by glucose and interleukin-1β. J. Clin. Endocrinol. Metab. 89 (2004) 5059-5066
86. Lin C.Y., et al. Activation of peroxisome proliferator-activated receptor-γ by rosiglitazone protects human islet cells against human islet amyloid polypeptide toxicity by a phosphatidylinositol 3′-kinase-dependent pathway. J. Clin. Endocrinol. Metab. 90 (2005) 6678-6686
87. Higa M., et al. Troglitazone prevents mitochondrial alterations, β-cell destruction, and diabetes in obese prediabetic rats. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 11513-11518
88. Finegood D.T., et al. β-Cell mass dynamics in Zucker diabetic fatty rats. Rosiglitazone prevents the rise in net cell death. Diabetes 50 (2001) 1021-1029
89. Kawasaki F., et al. Structural and functional analysis of pancreatic islets preserved by pioglitazone in db/db mice. Am. J. Physiol. Endocrinol. Metab. 288 (2005) E510-E518
90. Ishida H., et al. Pioglitazone improves insulin secretory capacity and prevents the loss of β-cell mass in obese diabetic db/db mice: possible protection of β-cells from oxidative stress. Metabolism 53 (2004) 488-494
91. Buchanan T.A., et al. Preservation of pancreatic β-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes 51 (2002) 2796-2803
92. Wang C.Y., et al. TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-κB. Science 274 (1996) 784-787
93. Beg A.A., and Baltimore D. An essential role for NF-κB in preventing TNF-α-induced cell death. Science 274 (1996) 782-784
94. Heimberg H., et al. Inhibition of cytokine-induced NF-κB activation by adenovirus-mediated expression of a NF-κB super-repressor prevents β-cell apoptosis. Diabetes 50 (2001) 2219-2224
95. Giannoukakis N., et al. Protection of human islets from the effects of interleukin-1β by adenoviral gene transfer of an IκB repressor. J. Biol. Chem. 275 (2000) 36509-36513
96. Kopp E., and Ghosh S. Inhibition of NF-κB by sodium salicylate and aspirin. Science 265 (1994) 956-959
97. Kim S., et al. NF-κB prevents β-cell death and autoimmune diabetes in NOD mice. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 1913-1918
98. Fleischman A., et al. Salsalate improves glycemia and inflammatory parameters in obese young adults. Diabetes Care 31 (2008) 289-294
99. Bonner-Weir S., and Weir G.C. New sources of pancreatic β-cells. Nat. Biotechnol. 23 (2005) 857-861
100. Hui H., et al. Glucagon-like peptide 1 induces differentiation of islet duodenal homeobox-1-positive pancreatic ductal cells into insulin-secreting cells. Diabetes 50 (2001) 785-796
101. Stoffers D.A., et al. Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas. Diabetes 49 (2000) 741-748
102. Stoffers D.A., et al. Neonatal exendin-4 prevents the development of diabetes in the intrauterine growth retarded rat. Diabetes 52 (2003) 734-740
103. Tourrel C., et al. Glucagon-like peptide-1 and exendin-4 stimulate β-cell neogenesis in streptozotocin-treated newborn rats resulting in persistently improved glucose homeostasis at adult age. Diabetes 50 (2001) 1562-1570
104. Xu G., et al. Exendin-4 stimulates both β-cell replication and neogenesis, resulting in increased β-cell mass and improved glucose tolerance in diabetic rats. Diabetes 48 (1999) 2270-2276
105. Rolin B., et al. The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases β-cell mass in diabetic mice. Am. J. Physiol. Endocrinol. Metab. 283 (2002) E745-E752
106. Parnaud G., et al. Proliferation of sorted human and rat β-cells. Diabetologia 51 (2008) 91-100
107. Miettinen P.J., et al. Downregulation of EGF receptor signaling in pancreatic islets causes diabetes due to impaired postnatal β-cell growth. Diabetes 55 (2006) 3299-3308
108. Cras-Meneur C., et al. Epidermal growth factor increases undifferentiated pancreatic embryonic cells in vitro: a balance between proliferation and differentiation. Diabetes 50 (2001) 1571-1579
109. Song S.Y., et al. Expansion of Pdx1-expressing pancreatic epithelium and islet neogenesis in transgenic mice overexpressing transforming growth factor-α. Gastroenterology 117 (1999) 1416-1426
110. Tokui Y., et al. Neogenesis and proliferation of β-cells induced by human betacellulin gene transduction via retrograde pancreatic duct injection of an adenovirus vector. Biochem. Biophys. Res. Commun. 350 (2006) 987-993
111. Yamamoto K., et al. Recombinant human betacellulin promotes the neogenesis of β-cells and ameliorates glucose intolerance in mice with diabetes induced by selective alloxan perfusion. Diabetes 49 (2000) 2021-2027
112. Rooman I., et al. Gastrin stimulates β-cell neogenesis and increases islet mass from transdifferentiated but not from normal exocrine pancreas tissue. Diabetes 51 (2002) 686-690
113. Brand S.J., et al. Pharmacological treatment of chronic diabetes by stimulating pancreatic β-cell regeneration with systemic co-administration of EGF and gastrin. Pharmacol. Toxicol. 91 (2002) 414-420
114. Suarez-Pinzon W.L., et al. Combination therapy with epidermal growth factor and gastrin increases β-cell mass and reverses hyperglycemia in diabetic NOD mice. Diabetes 54 (2005) 2596-2601
115. Rooman I., and Bouwens L. Combined gastrin and epidermal growth factor treatment induces islet regeneration and restores normoglycaemia in C57Bl6/J mice treated with alloxan. Diabetologia 47 (2004) 259-265
116. Wang T.C., et al. Pancreatic gastrin stimulates islet differentiation of transforming growth factor-α-induced ductular precursor cells. J. Clin. Invest. 92 (1993) 1349-1356
117. von Herrath M. E1-INT (Transition Therapeutics/Novo Nordisk). Curr. Opin. Investig. Drugs 6 (2005) 1037-1042